30-day mortality following initiation of immunotherapy for advanced stage lung cancer

Evans, Joanne; Kitson, R.; Shah, Raj C.; Li, S.; Ghosh, Sue; Pouptsis, Athanasios; Ahmed, Sameera; Walter, Harriet S.; Ahmad, Tauseef; Asghar, Uzma; Lester, J.F.; Newsom-Davis, Tom

doi:10.1016/s0169-5002(18)30108-9

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Considerations for obtaining optimal responses to immunotherapy in NSCLC In addition to treatment sequence, appropriate patient selection is crucial to ensure maximal benefit without undue risk. 44 Improved understanding of immune biology has led to the discovery of further predictive biomarkers of response beyond PD-L1 expression, including tumour mutational burden (TMB) 13,45 and immune gene signatures. 14 Challenges faced with these biomarkers include adequate tissue sampling, a robust reproducible diagnostic assay, intra-tumoural heterogeneity of TMB and PD-L1 expression and inter-tumoural heterogeneity in patterns of response to ICIs.…”

Section: The Evolving Landscape Of Treatment For Advanced Non-small-cmentioning

confidence: 99%

Beyond chemoradiotherapy: improving treatment outcomes for patients with stage III unresectable non-small-cell lung cancer through immuno-oncology and durvalumab (Imfinzi®▼, AstraZeneca UK Limited)

Patel

Alrifai²,

McDonald

et al. 2020

Br J Cancer

View full text Add to dashboard Cite

The treatment paradigm of non-small-cell lung cancer (NSCLC) has rapidly changed in recent years following the introduction of immune-checkpoint inhibition (ICI). Pre-clinically, both chemotherapy and radiotherapy modulate the tumour microenvironment, providing the rationale for clinical trials evaluating their role in combination with immunotherapy. Standard-of-care treatment for patients with unresectable stage III disease is concurrent chemoradiotherapy (cCRT); however, only recently, the combination with ICI has been explored. The Phase 3 PACIFIC study randomised 713 patients with confirmed locally advanced, unresectable, stage III NSCLC, whose disease has not progressed following cCRT, to either the anti-programmed death-ligand 1 (PD-L1) agent durvalumab (Imfinzi®▼, AstraZeneca UK Limited) or placebo. Patients with a PD-L1 status ≥1% treated with durvalumab had a significantly longer median progression-free survival compared with placebo (17.2 vs. 5.6 months, respectively; HR: 0.51; 95% CI: 0.41–0.63), prolonged median overall survival (OS) (NR vs. 28.7 months, respectively; HR: 0.68; 99.73% CI: 0.47–0.997; P = 0.0025) and long-term clinical benefit (3-year OS HR: 0.69; 95% CI: 0.55–0.86). Grade 3 or 4 toxicity was marginally greater in the durvalumab cohort versus placebo (30.5% vs. 26.1%). Based on these results, durvalumab has been licensed in this setting, and further clinical trials are exploring the use of ICI in unresectable stage III NSCLC.

show abstract

Section: The Evolving Landscape Of Treatment For Advanced Non-small-cmentioning

confidence: 99%

Beyond chemoradiotherapy: improving treatment outcomes for patients with stage III unresectable non-small-cell lung cancer through immuno-oncology and durvalumab (Imfinzi®▼, AstraZeneca UK Limited)

Patel

Alrifai²,

McDonald

et al. 2020

Br J Cancer

View full text Add to dashboard Cite

show abstract

Thirty-day Mortality Rates After Immunotherapy Initiation

et al. 2021

View full text Add to dashboard Cite

Background: The aim of this study was to determine the cause of death in patients who died within 30 days after the first dose of immunotherapy. Methods: The data of 1432 patients treated with immunotherapy in six tertiary referral hospitals were retrospectively analyzed. Results: It was determined that 34 (2%) of the patients died within 30 days after the first dose of immunotherapy. Death occurred in all patients who received palliative therapy, and most patients (88%) received immunotherapy as second- or subsequent-line of therapy. The most common cause of death was disease progression and thromboembolic events. Conclusion: Preliminary results of the current study might give some clues to define the patient population in whom the fatal side effects of immunotherapy might be encountered.

show abstract

30-day mortality following initiation of immunotherapy for advanced stage lung cancer

Cited by 2 publications

References 0 publications

Beyond chemoradiotherapy: improving treatment outcomes for patients with stage III unresectable non-small-cell lung cancer through immuno-oncology and durvalumab (Imfinzi®▼, AstraZeneca UK Limited)

Beyond chemoradiotherapy: improving treatment outcomes for patients with stage III unresectable non-small-cell lung cancer through immuno-oncology and durvalumab (Imfinzi®▼, AstraZeneca UK Limited)

Thirty-day Mortality Rates After Immunotherapy Initiation

Contact Info

Product

Resources

About